Billerica, Mass., USA – Lantheus MI Holdings, Inc., a parent company of Lantheus Medical Imaging, Inc., announced the appointment of Brian A. Markison as a member of its board of directors.[break]
Mr. Markison is a seasoned executive with more than 30 years of operational, marketing, commercial development and sales experience with international pharmaceutical companies. He most recently held the position of President and Chief Executive Officer and member of the Board of Directors of Fougera Pharmaceuticals Inc., a specialty pharmaceutical company in dermatology, prior to its sale to Sandoz, the generics division of Novartis AG.
Prior to joining Fougera, Mr. Markison served as Chairman, President and Chief Executive Officer of King Pharmaceuticals, Inc., which he joined as Chief Operating Officer. Prior to joining King, Mr. Markison served as President, Oncology/Virology and Oncology Therapeutics Network at Bristol - September 13, 2012, Billerica, Mass., USA – Lantheus MI Holdings, Inc., a parent company of Lantheus Medical Imaging, Inc., announced the appointment of Brian A. Markison as a member of its board of directors.
Article continues below
]
Mr. Markison is a seasoned executive with more than 30 years of operational, marketing, commercial development and sales experience with international pharmaceutical companies. He most recently held the position of President and Chief Executive Officer and member of the Board of Directors of Fougera Pharmaceuticals Inc., a specialty pharmaceutical company in dermatology, prior to its sale to Sandoz, the generics division of Novartis AG.
Prior to joining Fougera, Mr. Markison served as Chairman, President and Chief Executive Officer of King Pharmaceuticals, Inc., which he joined as Chief Operating Officer. Prior to joining King, Mr. Markison served as President, Oncology/Virology and Oncology Therapeutics Network at Bristol-Myers Squibb.
Mr. Markison also previously held a number of senior leadership positions throughout his 22-year tenure at Bristol-Myers Squibb, including Senior Vice President, Licensing & External Development and Mergers/Acquisitions; Vice President, Operational Excellence and Productivity; President, Neuroscience/Infectious Disease/Dermatology/U.S. Managed Care; and Vice President, Strategy and Economics U.S. Pharma.
Mr. Markison currently serves as Lead Director and Chair of the Compensation Committee for the Board of Directors of Immunomedics, Inc., a biopharmaceutical company focusing on antibody-based therapeutics for the treatment of cancer auto immune and other serious diseases); Chairman of the Board of Directors for Rosetta Genomics, a leading developer of microRNA-based molecular diagnostics; and Director and Compensation Committee Chair for PharmAthene, a bio-defense company developing medical countermeasures against biological and chemical threats. ■